Search
MK-0354
go.drugbank.com/drugs/DB05939InvestigationalMK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.
4'-Methylene-5,8,10-trideazaaminopterin
go.drugbank.com/drugs/DB05616InvestigationalCH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier
Reproxalap
go.drugbank.com/drugs/DB16688InvestigationalReproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis
Efavaleukin alfa
go.drugbank.com/drugs/DB16149InvestigationalEfavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker.
Avenciguat
go.drugbank.com/drugs/DB18882InvestigationalAvenciguat is under investigation in clinical trial NCT05282121 (A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis
AVR-RD-01
go.drugbank.com/drugs/DB17651InvestigationalAVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc.
beta-Alanine
go.drugbank.com/drugs/DB03107Investigationalbeta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].